Option Care Health, Inc. (OPCH) Stock

Understand Option Care Health, Inc.: how it makes money

Option Care Health bills payers for IV infusions, nutritional support, and immunoglobulin therapies delivered at patients' homes or smaller clinics instead of hospital settings. Revenue is weighted toward chronic inflammatory disease and anti-infective infusions, with a developing mix of rare-therapy and ambulatory-clinic visits adding complexity over time.

Profit is a thin residual of infusion visit volume minus skilled-nursing labor cost; payer reimbursement sets the ceiling, and a 5% operating margin leaves almost no cushion for a volume dip.

Business quality (Weak): The stock trades at a 25% discount to the Healthcare Services sector, yet sub-6% operating margins and a 19% gross margin reflect a labor-heavy delivery model with limited pricing leverage, so the earnings base stays fragile even at a cheap multiple.

Valuation: At 19× earnings, OPCH trades 25% below the Healthcare Services average (25×).

Bull case

• 25% below sector multiple: OPCH trades at 19.1x earnings versus the Healthcare Services industry average of 25x, a 25% discount. If CID recovery and ambulatory clinic expansion deliver as management hints, the multiple has visible room to re-rate toward the peer norm.
• Rare-therapy launches broaden the mix: Management noted that rare and orphan therapies delivered broad growth in the quarter, with additional launches ahead. Adding higher-complexity procedures diversifies revenue away from the lumpy CID base and can lift average reimbursement per visit.

Bear case

• CID headwinds squeeze thin margins: Management confirmed CID headwinds remain a major drag on both revenue and gross profit. With quarterly revenue at $1.4B and only 19% gross / 5% operating margin, further CID volume erosion would push profitability toward breakeven quickly.
• Competitive field caps pricing power: The infusion market is highly competitive, and management stressed that continued execution is required just to retain demand. At a 5% operating margin, even a modest pricing concession or share loss flows straight to the bottom line.
• No guidance past fiscal 2026: Management has not provided 2027 guidance, and new-therapy contributions depend partly on regulatory approvals and other external factors. The two-year revenue path is therefore harder to underwrite than the sector median, adding an uncertainty premium for holders.

Related Companies (Healthcare Services; 8 comparable companies)

• AdaptHealth Corp. (AHCO)
• Chemed Corporation (CHE)
• BrightSpring Health Services, Inc. Common Stock (BTSG)
• Aveanna Healthcare Holdings Inc. (AVAH)
• Addus HomeCare Corporation (ADUS)
• Select Medical Holdings Corporation (SEM)
• Agilon Health, Inc. (AGL)
• Encompass Health Corporation (EHC)